Certain Assets of GE Healthcare CodeLink Gene Expression Bioarray System Sustainability Profile
GE Healthcare, a subsidiary of General Electric, is a leading player in the global healthcare industry, headquartered in the United States. Founded in 1892, the company has consistently innovated in medical imaging, monitoring, biomanufacturing, and diagnostics, with a strong focus on enhancing patient care and operational efficiency. The CodeLink Gene Expression Bioarray System is one of GE Healthcare's core offerings, distinguished by its ability to provide comprehensive gene expression analysis. This system enables researchers to gain insights into complex biological processes, making it invaluable in both clinical and research settings. With a robust market position, GE Healthcare has achieved numerous milestones, including advancements in molecular imaging and personalised medicine, solidifying its reputation as a trusted partner in the healthcare sector.
DitchCarbon Score
How does Certain Assets of GE Healthcare CodeLink Gene Expression Bioarray System's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Certain Assets of GE Healthcare CodeLink Gene Expression Bioarray System's score of 21 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Certain Assets of GE Healthcare CodeLink Gene Expression Bioarray System currently does not report specific carbon emissions data, as no emissions figures are available. The organisation is part of a corporate family that cascades emissions data from Schott AG, a parent company at cascade level 3. However, there are no documented reduction targets or climate pledges associated with this entity. As a merged entity, Certain Assets of GE Healthcare CodeLink Gene Expression Bioarray System may align with broader sustainability initiatives from Schott AG, which may include commitments to reduce emissions and improve environmental performance. Nonetheless, without specific data or targets, it is challenging to assess their individual climate commitments or achievements. In the context of the industry, it is essential for organisations to establish clear carbon reduction strategies and report emissions transparently to contribute effectively to global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Scope 1 | - | - | - |
| Scope 2 | - | - | - |
| Scope 3 | - | - | - |
How Carbon Intensive is Certain Assets of GE Healthcare CodeLink Gene Expression Bioarray System's Industry?
How Carbon Intensive is Certain Assets of GE Healthcare CodeLink Gene Expression Bioarray System's Location?
Certain Assets of GE Healthcare CodeLink Gene Expression Bioarray System's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Certain Assets of GE Healthcare CodeLink Gene Expression Bioarray System has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
